Moderna, Inc. — Director's Dealing 2021

Feb 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2021-02-08

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-08	Common Stock	M	3670	$12.21	Acquired	3670	Direct
2021-02-08	Common Stock	S	100	$178.20	Disposed	3570	Direct
2021-02-08	Common Stock	S	300	$179.43	Disposed	3270	Direct
2021-02-08	Common Stock	S	100	$180.74	Disposed	3170	Direct
2021-02-08	Common Stock	S	400	$182.92	Disposed	2770	Direct
2021-02-08	Common Stock	S	1404	$185.03	Disposed	1366	Direct
2021-02-08	Common Stock	S	566	$185.82	Disposed	800	Direct
2021-02-08	Common Stock	S	800	$186.84	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-08	Stock Option (Right to Buy)	$12.21	M	3670	Disposed	2027-10-03	Common Stock (3670)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $179.27 to $179.53. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $182.89 to $182.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $184.43 to $185.43. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $185.49 to $186.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $186.53 to $187.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F7: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).